Liquidia challenges regulatory exclusivity for rival's inhaled drug (updated)

United Therapeutics

22/08/2024 11:22

(Recasts, adds details in paragraphs 2-3)
       Aug 22 (Reuters) - Liquidia Corp  LQDA.O  has filed a
legal challenge to the U.S. Food and Drug Administration's
decision to grant three-year exclusivity to United Therapeutics'
 UTHR.O  inhaled drug used to treat lung disorders, it said on
Thursday.
    The FDA on Monday granted regulatory exclusivity to United's
Tyvaso DPI, which delays traditional approval for Liquidia's
inhaled drug, yutrepia.
    Tyvaso DPI and yutrepia are inhaled drugs used to treat
pulmonary arterial hypertension (PAH) and pulmonary hypertension
associated with interstitial lung disease (PH-ILD).
    Liquidia filed the litigation in the district court of the 
District of Columbia.       
    
     

 (Reporting by Sneha S K; Editing by Mrigank Dhaniwala)
 ((Sneha.SK@thomsonreuters.com;))